The results of a small clinical trial have found that there could be a cure for rectal cancer.
The trial — conducted by Memorial Sloan Kettering Cancer Center in Manhattan — involved at least 12 cancer” target=”_blank”>rectal cancer patients<
The American Cancer Society estimates that in 2022, there will be 44,850 new cases of rectal cancer.
Colorectal cancer is the second most common cause of cancer deaths in the U.S., according to the organization.
This year, colorectal cancer is expected to cause 52,580 deaths, the American Cancer Society estimates.
A small clinical trial of the drug dostarlimab was found to completely cure 12 patients of rectal cancer.
(iStock)
The patients involved in the clinical trial all had tumors with a specific genetic makeup known as mismatch repair-deficient (MMRd), a press release from Memorial Sloan Kettering indicated.
The release said that between 5% and 10% of rectal cancer patients have MMRd tumors.
ST. JUDE PATIENT DESIGNS MONSTER JAM TOY TRUCK, SURPRISED WITH REAL DEAL: ‘JUST AWESOME’
None of the medical-research” target=”_blank”>clinical trial patients<
Cercek is one of the co-authors of the paper, which was presented on Sunday at the American Society of Clinical Oncology.
“It’s really exciting,” Dr. Luis Diaz, Jr., another Memorial Sloan Kettering oncologist and a co-author of the paper, said in the release.
“Longer follow-up is needed to assess the duration of response.”
“I think this is a great step forward for patientsa>.”<
The clinical trial is continuing to enroll patients with MMRd rectal cancer tumors, the Memorial Sloan Kettering press release said.
FOLLOW US ON FACEBOOK FOR MORE FOX LIFESTYLE NEWS
The cancer center is also looking into how dostarlimab might be able to help patients with other kinds of cancer that have MMRd tumors as well, such as stomach, prostate and pancreatic cancer.
